Main Management’s iShares Biotechnology ETF IBB Stock Holding History

Main Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300	Closed	-$51K	–	98
2026 Q1	$51K	Hold	300	–	–	﹤0.01%	78
2025 Q4	$51K	Hold	300	–	–	﹤0.01%	82
2025 Q3	$43K	Hold	300	–	–	﹤0.01%	88
2025 Q2	$38K	Hold	300	–	–	﹤0.01%	89
2025 Q1	$38K	Hold	300	–	–	﹤0.01%	94
2024 Q4	$40K	Sell	300 -152	-34%	-$21.4K	﹤0.01%	103
2024 Q3	$66K	Hold	452	–	–	0.01%	85
2024 Q2	$62K	Hold	452	–	–	0.01%	95
2024 Q1	$62K	Hold	452	–	–	0.01%	97
2023 Q4	$61K	Sell	452 -4,500	-91%	-$549K	0.01%	89
2023 Q3	$606K	Sell	4,952 -4,500	-48%	-$572K	0.06%	49
2023 Q2	$1.2M	Buy	9,452 +9,000	+1,991%	+$1.17M	0.12%	44
2023 Q1	$58K	Sell	452 -32	-7%	-$4.19K	0.01%	100
2022 Q4	$64K	Sell	484 -63,740	-99%	-$8.24M	0.01%	111
2022 Q3	$7.51M	Buy	64,224 +263	+0.4%	+$32.7K	0.93%	27
2022 Q2	$7.52M	Buy	63,961 +1,217	+2%	+$144K	0.9%	29
2022 Q1	$8.18M	Sell	62,744 -5,589	-8%	-$728K	0.84%	27
2021 Q4	$10.4M	Buy	68,333 +5,417	+9%	+$839K	1.04%	28
2021 Q3	$10.2M	Buy	62,916 +603	+1%	+$101K	1.09%	24
2021 Q2	$10.2M	Sell	62,313 -269	-0.4%	-$41.4K	1.1%	25
2021 Q1	$9.42M	Buy	62,582 +336	+0.5%	+$53.4K	1.05%	28
2020 Q4	$9.43M	Sell	62,246 -1,423	-2%	-$203K	1.21%	24
2020 Q3	$8.62M	Buy	63,669 +2,272	+4%	+$308K	1.21%	24
2020 Q2	$8.39M	Buy	61,397 +4,693	+8%	+$598K	1.33%	25
2020 Q1	$6.11M	Sell	56,704 -5,198	-8%	-$598K	1.13%	25
2019 Q4	$7.46M	Sell	61,902 -245,314	-80%	-$27.4M	1%	24
2019 Q3	$30.6M	Sell	307,216 -49,509	-14%	-$5.18M	4.25%	7
2019 Q2	$38.9M	Buy	356,725 +853	+0.2%	+$90.7K	5.66%	5
2019 Q1	$39.8M	Sell	355,872 -43,115	-11%	-$4.73M	5.86%	5
2018 Q4	$38.5M	Buy	398,987 +49,514	+14%	+$5.26M	5.88%	5
2018 Q3	$42.6M	Sell	349,473 -114,835	-25%	-$13.5M	6.14%	4
2018 Q2	$51M	Buy	464,308 +3,726	+0.8%	+$398K	6.87%	4
2018 Q1	$49.2M	Sell	460,582 -1,219	-0.3%	-$135K	6.73%	4
2017 Q4	$49.3M	Sell	461,801 -15,085	-3%	-$1.61M	7.16%	3
2017 Q3	$53M	Sell	476,886 -2,280	-0.5%	-$244K	7.88%	3
2017 Q2	$49.5M	Buy	479,166 +2,346	+0.5%	+$231K	7.58%	4
2017 Q1	$46.6M	Buy	476,820 +1,086	+0.2%	+$104K	7.49%	4
2016 Q4	$42.1M	Buy	475,734 +258,342	+119%	+$23.5M	7.27%	5
2016 Q3	$21M	Buy	+217,392	New	+$20.7M	4.13%	6

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Main Management's IBB Position: Q2 2026 in Review

Main Management sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 300 shares — an estimated $51K sold.

Main Management first reported a position in IBB in Q3 2016 and held it in 39 quarters. The position peaked at $53M in Q3 2017. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Main Management reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
Main Management sold 300 iShares Biotechnology ETF shares in Q2 2026, an estimated $51K.
Main Management first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 39 quarters.
Main Management's iShares Biotechnology ETF position peaked at $53M in Q3 2017.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Main Management's 13F filing for Q2 2026, filed 14 Aug 2026.